Breakthrough in Retinal Disease Treatment Offers Hope

For individuals and families navigating the challenges of inherited retinal diseases (IRDs) and other vision-threatening conditions, news of advancements in treatment development offers significant hope. Ollin Biosciences, a clinical-stage biotech company, has announced promising results from an early-stage trial of its bispecific antibody, OLN324, which is now poised to enter global Phase 3 clinical trials for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) in the second half of 2026. This development signals potential new options for managing these complex eye conditions.

Ollin Biosciences recently secured an oversubscribed $330 million in Series B financing to support the global Phase 3 development of OLN324. This substantial investment underscores the confidence in OLN324's potential, particularly after its performance in an early-stage trial.

Key Findings from Early-Stage Trial

OLN324 is a next-generation bispecific antibody that targets both VEGF (vascular endothelial growth factor) and Ang-2 (angiopoietin-2), which are key drivers of retinal vascular diseases. In a head-to-head Phase 1b clinical study, known as JADE, OLN324 was compared to Vabysmo (faricimab), a current treatment for DME and wAMD.

The JADE study, which involved 164 patients with either DME or wAMD, demonstrated that OLN324 produced meaningfully faster and greater improvements in retinal anatomy compared to Vabysmo in both conditions. Specifically, in patients with DME, OLN324 showed faster and more durable drying of the retina. The study also reported numerically greater vision gains for patients treated with OLN324 across both DME and wAMD cohorts.

Ollin Biosciences attributes OLN324's potential advantages to its higher potency for Ang-2 and its smaller size, which may allow it to penetrate deeper into retinal tissue more easily after injection.

What This Means for Patients and Families

While the initial focus of OLN324 is on DME and wAMD, successful development of such advanced therapies can pave the way for broader understanding and treatment approaches in retinal diseases. The prospect of a therapy that offers faster and greater anatomical improvements, along with better vision outcomes, could significantly impact the quality of life for many patients. Faster disease clearance and improved retinal drying, as observed in the early trial, are strongly associated with better vision.

Ollin Biosciences has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA) regarding the Phase 3 program. This indicates that the company is moving forward with regulatory guidance for its larger, pivotal trials.

Looking Ahead

Ollin Biosciences plans to initiate global Phase 3 trials for OLN324 in both DME and wAMD during the second half of 2026. These upcoming trials will further evaluate the safety and efficacy of OLN324, moving it closer to potential availability as a new treatment option. The company aims for OLN324 to become a new standard of care in retinal vascular disease.